MIRA PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MIRA PHARMACEUTICALS, INC. | ||
| Date: March 31, 2026 | By: | /s/ Erez Aminov |
|---|---|---|
| Name: | Erez Aminov | |
| Title: | Chief Executive Officer | |
| (Principal Executive Officer) | ||
| By: | /s/ Alan Weichselbaum | |
| Name: | Alan Weichselbaum | |
| Title: | Chief Financial Officer | |
| (Principal Financial Officer) | ||
In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Person | Capacity | Date |
|---|---|---|
| /s/ Erez Aminov | Chief Executive Officer and Chairman | March 31, 2026 |
| Erez Aminov | ||
| /s/ Alan Weichselbaum | Chief Financial Officer | March 31, 2026 |
| Alan Weichselbaum | ||
| /s/ Matthew Whalen | Director | March 31, 2026 |
| Matthew Whalen | ||
| /s/ Matthew Del Giudice | Director | March 31, 2026 |
| Matthew Del Giudice | ||
| /s/ Denil Shekhat | Director | March 31, 2026 |
| Denil Shekhat | ||
| /s/ Edward MacPherson | Director | March 31, 2026 |
| Edward MacPherson | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.